Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669504 | 0.92 | CETP (0.37) | CETPTACR1PTGDR2GPBAR1 | |
| SCHEMBL1896189 | 0.91 | CETP (0.44) | CETPPTGDR2 | |
| SCHEMBL5669136 | 0.87 | CETP (0.34) | CETPRXRARXRGPTGESGPBAR1 | |
| SCHEMBL5148310 | 0.86 | RXRA (0.34) | CETPRXRARXRGTACR1PTGES | |
| SCHEMBL1902676 | 0.85 | TACR1 (0.32) | TACR1 | |
| SCHEMBL5670981 | 0.85 | CETP (0.37) | CETPTACR1PTGDR2GPBAR1 | |
| SCHEMBL5669609 | 0.85 | CETP (0.37) | CETPTACR1PTGDR2GPBAR1 | |
| SCHEMBL1897361 | 0.85 | CETP (0.33) | CETPRXRARXRGTACR1PTGES | |
| SCHEMBL5670667 | 0.84 | RXRA (0.34) | CETPRXRARXRGTACR1PTGES | |
| SCHEMBL5670023 | 0.83 | RXRA (0.34) | CETPRXRARXRGTACR1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | claimed |
| US-9724362-B2 | Pharmaceutical compositions comprising nanoparticles and a resuspending material | BEND RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9545384-B2 | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate | BEND RESEARCH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2231169-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2162120-B1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-8974827-B2 | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer | BEND RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8703204-B2 | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100323014-A1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100310663-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | LONZA BEND INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100183731-A1 | NANOPARTICLES COMPRISING DRUG, A NON-IONIZABLE CELLULOSIC POLYMER AND TOCOPHERYL POLYETHYLENE GLOCOL SUCCINATE | LONZA BEND INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100129447-A1 | NANOPARTICLES COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND ANON-IONIZABLE POLYMER | BEND RESEARCH, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100119612-A1 | NANOPARTICLES COMPRISING NON-CRYSTALLINE DRUG | BEND RESEARCH, INC | 2010-05-13 | — | — | US | disclosed |
| US-20100080852-A1 | PHAMACEUTICAL COMPOSITION COMPRISING NANOPARTICLES AND CASEIN | BEND RESEARCH, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2008149230-A2 | NANOPARTICLES COMPRISING DRUG, A NON-IONIZABLE CELLULOSIC POLYMER AND TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE | PFIZER PRODUCTS INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008135852-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND CASEIN | PFIZER PRODUCTS INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008125940-A2 | NANOPARTICLES COMPRISING NON-CRYSTALLINE DRUG | PFIZER PRODUCTS INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323014-A1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | LRBA, CEL, TNNC1 | CETP 280/4885RXRA 2008/4885RXRG 2064/4885 |
| US-20100129447-A1 | NANOPARTICLES COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND ANON-IONIZABLE POLYMER | CETP, CHLSN, PCTP | CETP 1/4885RXRA 3902/4885RXRG 3516/4885 |
| US-20100310663-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | SUCLG2, SORD, ACMSD | CETP 136/4885RXRA 4238/4885RXRG 4035/4885 |
| US-20100080852-A1 | PHAMACEUTICAL COMPOSITION COMPRISING NANOPARTICLES AND CASEIN | PACSIN2, CSNK1A1, CSNK1G1 | CETP 62/4885RXRA 3121/4885RXRG 3098/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CETP 1/4885RXRA 2112/4885RXRG 2127/4885 |
| US-20100183731-A1 | NANOPARTICLES COMPRISING DRUG, A NON-IONIZABLE CELLULOSIC POLYMER AND TOCOPHERYL POLYETHYLENE GLOCOL SUCCINATE | GLO1, PGLS, TTPA | CETP 74/4885RXRA 3188/4885RXRG 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.